Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inspire Pharmaceuticals, a biopharmaceutical company, has initiated a Phase I clinical trial with INS117548 ophthalmic solution for the treatment of glaucoma.
Subscribe to our email newsletter
The placebo-controlled, dose-escalating trial is designed to evaluate the safety, tolerability and intraocular pressure (IOP)-lowering effects of INS117548 in approximately 60 subjects with early stage glaucoma or ocular hypertension.
INS117548 is a Rho kinase inhibitor designed to lower IOP in glaucoma patients by disrupting the actin cytoskeleton of the trabecular meshwork, an ocular tissue responsible for most of the outflow of aqueous humor. Inspire also has a latrunculin B compound, INS115644, related to this platform that is in Phase I clinical testing.
Kim Brazzell, senior vice president of ophthalmic R&D at Inspire, said: “We are pleased to begin clinical testing of INS117548 since it represents a novel approach to lowering intraocular pressure. This is an important milestone for Inspire as it strengthens our ophthalmic pipeline in disease states with unmet medical need such as glaucoma, which is the second leading cause of blindness in the US.”